Safety, Efficacy, and Pharmacokinetics Study of Tarceva to Treat Advanced Colorectal Cancer
Phase 1
Completed
- Conditions
- Colorectal Cancer
- Registration Number
- NCT00047762
- Lead Sponsor
- Genentech, Inc.
- Brief Summary
The purpose of this study is test the safety of Tarceva, find the best dose, and see what effects (good and bad) it has on you and your colorectal cancer. The effects of Tarceva will be evaluated in combination with 5-fluorouracil, leucovorin, and irinotecan, with or without Bevacizumab.
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Not provided
Exclusion Criteria
Not provided
Study & Design
- Study Type
- INTERVENTIONAL
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method
Trial Locations
- Locations (3)
Johns Hopkins Oncology Center
🇺🇸Baltimore, Maryland, United States
Indiana University Cancer Pavilion
🇺🇸Indianapolis, Indiana, United States
Mary Crowley Medical Research Center
🇺🇸Dallas, Texas, United States